KDR and neoplasm: Current studies suggest that VEGF has immunosuppressive effects and that anti-angiogenic drugs targeting VEGF-VEGFR can increase T cell activity and promote infiltration and activation of CD8+ T cells in the tumor microenvironment, thus acting synergistically with ICIs (26).